Compare JCSE & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JCSE | BIAF |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 9.2M |
| IPO Year | 2022 | 2022 |
| Metric | JCSE | BIAF |
|---|---|---|
| Price | $1.48 | $3.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.3K | ★ 3.0M |
| Earning Date | 10-29-2026 | 11-13-2026 |
| Dividend Yield | ★ 29.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,900,000.00 |
| Revenue This Year | N/A | $18.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.49 |
| 52 Week Low | $0.77 | $0.37 |
| 52 Week High | $2.50 | $21.52 |
| Indicator | JCSE | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 37.59 |
| Support Level | $1.32 | $3.31 |
| Resistance Level | $1.56 | $4.35 |
| Average True Range (ATR) | 0.05 | 0.80 |
| MACD | 0.01 | -0.41 |
| Stochastic Oscillator | 50.00 | 8.05 |
JE Cleantech Holdings Ltd is engaged in the manufacturing and selling of cleaning systems and other equipment that can be categorized into four different categories, namely aqueous washing systems, plating and cleaning systems, train cleaning systems, and other equipment, such as filtration units. The company is also into designing, developing, and manufacturing other cleaning systems for various industrial end-use applications using its R&D and engineering capabilities. The company has two operating segments namely sale of cleaning systems and other equipment and provision of centralized dishware washing and general cleaning services. Geographically, the company derives a majority of its revenue from Singapore.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.